Span Divergent Quarterly Results
Span Divergent quarterly results. In Sept 2025, Span Divergent (SDL) reported revenue ₹8 Cr and net profit ₹0 Cr — revenue +166.7% YoY. Review SDL earnings multiple to evaluate earnings-based valuation against sector peers.
SDL Quarterly Results — Revenue, Profit & EPS Highlights
Span Divergent latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check Span Divergent marketcap in USD to track the company's total market size over time.
- Revenue of ₹8 Cr in Sept 2025 (+700.0% vs Mar 2025, +166.7% vs Sept 2024)
- Operating Margin of -1.0% in Sept 2025 (+197.0pp vs Mar 2025)
- Earnings Per Share of ₹-0.34 in Sept 2025 (+81.8% vs Mar 2025)
Span Divergent Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SDL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 8 | 1 | 2 | 3 | 4 | 700.0% | 166.7% |
| Net Profit (₹ Cr) | 0 | -1 | 0 | 0 | 1 | - | - |
| EBITDA (₹ Cr) | 0 | -1 | 0 | 0 | 1 | - | - |
| EPS (₹) | -0.34 | -1.87 | -0.31 | 0.09 | 1.62 | - | - |
| Operating Margin (%) | -1.0% | -198.0% | -81.0% | 5.0% | -2.0% | - | - |
SDL Share Price Trend — 1-Year Movement Across Quarterly Results
Span Divergent 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Span Divergent share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SDL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Span Divergent latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Cipla
Mar 2026 |
₹108,576.18 Cr | 1335.5 | 6,612 | 543 | -9.3% | - | 8.2% | 194.4 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores